Last updated: October 19, 2026
Amipaque was a branded formulation of metrizamide, an early nonionic, water-soluble iodinated contrast medium used mainly for intrathecal myelography and related diagnostic imaging. Its commercial value declined as newer low-osmolar contrast agents, improved imaging technology, and less invasive diagnostic methods displaced metrizamide. Amipaque is no longer a meaningful commercial product, has no active U.S. market presence, and does not have a publicly reported standalone revenue stream.
What was Amipaque and how was metrizamide used?
Amipaque contained metrizamide, a nonionic iodinated contrast agent developed for radiographic visualization of the spinal canal and other anatomical structures. The product was administered intrathecally for myelography, a procedure used to identify spinal stenosis, disc disease, tumors, and other abnormalities before the widespread adoption of magnetic resonance imaging.
Metrizamide had a lower adverse-effect burden than earlier ionic contrast agents. Its nonionic structure reduced, but did not eliminate, the risk of pain, neurotoxicity, seizures, nausea, and other complications associated with intrathecal contrast administration.
| Product attribute |
Amipaque profile |
| Brand name |
Amipaque |
| Active ingredient |
Metrizamide |
| Drug class |
Nonionic iodinated contrast medium |
| Primary use |
Intrathecal myelography |
| Route |
Intrathecal injection |
| Commercial developer |
Associated historically with Nyegaard, later Nycomed |
| Market period |
Primarily 1970s through 1990s |
| Current status |
Commercially obsolete or discontinued in major markets |
| Current U.S. Orange Book status |
No marketed Amipaque product identified in current FDA listings |
| Main substitutes |
Iopamidol, iohexol, and other modern low-osmolar contrast agents; MRI |
Metrizamide is identified in chemical and pharmacological databases as an iodinated diagnostic agent rather than as a therapeutic small molecule with ongoing chronic-use demand (National Center for Biotechnology Information [NCBI], n.d.).
When did Amipaque lose commercial exclusivity?
Amipaque lost commercial relevance before the modern U.S. generic market became the principal driver of competition. Its decline resulted from therapeutic substitution rather than a single identifiable patent-expiration event.
The commercial sequence was:
- Metrizamide entered the market as a safer alternative to earlier intrathecal contrast agents.
- Other nonionic low-osmolar agents entered clinical use.
- Iohexol and iopamidol gained adoption because of broader applications, improved handling, and established hospital purchasing arrangements.
- MRI reduced the need for invasive myelography.
- Amipaque ceased to have a material commercial role.
Public sources do not establish one definitive global patent-expiration date for the Amipaque brand. Patent rights would have differed by jurisdiction, formulation, manufacturing process, and use. The product is old enough that any original composition-of-matter protection would have expired decades ago. Current commercial barriers are therefore not patent-based.
What was the financial trajectory of Amipaque?
No reliable public financial series reports Amipaque revenue, operating profit, or product-level margins. Historical manufacturers generally disclosed contrast-media revenue at the portfolio or company level rather than by individual brand.
The financial trajectory can be characterized in four phases:
| Phase |
Commercial conditions |
Financial direction |
| Launch and adoption |
Clinical demand for safer intrathecal imaging agents |
Revenue growth from substitution for older ionic agents |
| Expansion |
Use in myelography and selected diagnostic procedures |
Moderate commercial expansion |
| Competitive erosion |
Entry of newer nonionic agents with broader use profiles |
Declining market share and pricing pressure |
| Obsolescence |
MRI adoption and withdrawal or replacement of older products |
Near-zero branded revenue |
Amipaque’s economic value was concentrated in its early lifecycle. Once physicians adopted newer nonionic agents and MRI became standard for many spinal indications, metrizamide no longer supported a durable premium.
The product’s financial decline was likely driven by volume loss rather than a sharp patent cliff. That distinction matters. A patent cliff normally allows generic manufacturers to enter a still-large market. Amipaque instead lost demand as the underlying procedure declined and competing products became preferred.
How did Amipaque compare with iohexol and iopamidol?
Amipaque competed in the broader nonionic contrast-media market but had a narrower commercial position than later products.
| Factor |
Amipaque, metrizamide |
Iohexol |
Iopamidol |
| Primary historical positioning |
Intrathecal myelography |
Broad radiographic and CT applications, including intrathecal use |
Broad radiographic and CT applications, including intrathecal use |
| Generation |
Early nonionic agent |
Later low-osmolar agent |
Later low-osmolar agent |
| Market breadth |
Relatively narrow |
Broad |
Broad |
| MRI substitution exposure |
High |
Moderate to high |
Moderate to high |
| Current commercial relevance |
Obsolete or discontinued |
Established generic and branded presence in some markets |
Established generic and branded presence in some markets |
| Strategic advantage |
Earlier safety improvement over ionic agents |
Broader indications and modern hospital adoption |
Broad indications and competitive availability |
The key competitive disadvantage was not simply price. Amipaque was tied to an invasive procedure that declined in frequency. Newer contrast agents were used across CT, angiography, urography, and other procedures, giving manufacturers better manufacturing scale and hospital-contract leverage.
What is the FDA regulatory status of Amipaque?
Amipaque does not appear to have an active marketed status in current U.S. FDA product databases. Current FDA databases identify approved and marketed products, but an absence of an active listing does not by itself establish the precise date or legal mechanism of discontinuation.
The FDA’s Orange Book is designed to identify approved drug products and related patent and exclusivity information. It is not a complete historical register of every discontinued product. Amipaque’s absence from current marketed listings is consistent with its obsolete commercial status, but it should not be interpreted as evidence of a recent withdrawal for safety reasons (U.S. Food and Drug Administration [FDA], n.d.-a; FDA, n.d.-b).
There is no current U.S. biosimilar issue because metrizamide is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway would have been an abbreviated or full generic drug application, not a biosimilar application.
What patents protected Amipaque and metrizamide?
Historical patent protection likely covered metrizamide composition, synthesis, purification, pharmaceutical formulations, and diagnostic use. The patent estate is no longer commercially meaningful.
No active, high-value U.S. patent estate is associated with Amipaque as a marketed product. Any original patents would have reached expiration many years ago, and modern patent term rules would not preserve protection for a product first commercialized in the 1970s.
Potential historical patent categories included:
- Metrizamide compound claims.
- Manufacturing and purification processes.
- Sterile aqueous formulations.
- Intrathecal administration methods.
- Packaging and reconstitution systems.
The absence of a current patent barrier means that a hypothetical manufacturer would not face meaningful exclusivity risk from the original Amipaque estate. The commercial problem would be market demand, clinical adoption, regulatory redevelopment, and manufacturing economics.
Were there Paragraph IV challenges or patent litigation?
No significant modern Paragraph IV campaign or U.S. patent litigation involving Amipaque is publicly associated with the product. That outcome is commercially logical. Paragraph IV litigation is most valuable when a branded product has substantial remaining sales and a generic applicant can capture a large market at launch.
Amipaque’s market had already contracted through clinical substitution. A generic challenge would have offered limited upside compared with generic entry against a high-volume contrast agent such as iohexol or iopamidol.
There is also no material public record of a major settlement agreement governing generic entry for Amipaque. Historical regulatory and litigation records may contain isolated disputes, but no widely recognized settlement shaped the current contrast-media market.
What manufacturing and intellectual-property barriers remain?
The original intellectual-property barrier is effectively gone. Manufacturing barriers remain practical rather than exclusionary.
A current manufacturer would need to address:
- Sterile injectable production.
- Control of iodine content and impurities.
- Stability in aqueous formulation.
- Intrathecal-use quality standards.
- Container-closure integrity.
- Validated aseptic processing.
- Clinical and regulatory requirements for an obsolete indication.
- Limited commercial scale.
Intrathecal products require tighter risk controls than many routine injectable products because administration occurs directly into the central nervous system. That requirement could make reintroduction expensive even without patent protection.
The largest barrier is likely demand uncertainty. A company would need to justify new regulatory, manufacturing, pharmacovigilance, and distribution costs for a product displaced by MRI and newer contrast agents.
Which companies challenged or replaced Amipaque?
The principal competitive pressure came from manufacturers of later nonionic contrast agents rather than from a single generic challenger. Relevant competitors included companies commercializing iohexol, iopamidol, iopromide, and related agents.
Historically important contrast-media companies included:
- Nycomed, associated with Amipaque and later broader contrast-media operations.
- GE Healthcare, associated with Omnipaque and other imaging agents.
- Bracco, associated with Isovue and other contrast products.
- Schering and later Bayer, associated with several radiographic contrast brands.
- Generic manufacturers supplying older and newer iodinated contrast media.
The market shifted toward suppliers with broad hospital portfolios, global manufacturing capacity, and products covering multiple imaging modalities. Amipaque’s narrower use profile limited its ability to compete for institutional contracts.
What is the generic launch risk for Amipaque?
Generic launch risk is currently low because the reference product has little or no active commercial presence. A new metrizamide entrant would not be responding to a conventional loss-of-exclusivity opportunity. It would be attempting to recreate a largely displaced market.
A hypothetical relaunch would face:
- Limited physician familiarity.
- Reduced use of myelography.
- MRI substitution.
- Competition from established nonionic contrast agents.
- Potentially high regulatory costs relative to expected volume.
- Weak pricing power in hospital procurement.
- Uncertain reimbursement and formulary placement.
The more relevant competitive risk lies with modern contrast agents and imaging modalities, not with a new generic version of Amipaque.
How strong is the Amipaque patent estate today?
The current patent estate is commercially weak to nonexistent. Original product protection has expired, and no active exclusivity appears to support a branded premium.
| Estate component |
Current commercial assessment |
| Composition-of-matter protection |
Expired |
| Formulation protection |
Expired or commercially irrelevant |
| Method-of-use protection |
Expired or commercially irrelevant |
| Manufacturing patents |
Not a meaningful market barrier |
| Regulatory exclusivity |
No current meaningful exclusivity identified |
| Patent litigation risk |
Low |
| Biosimilar risk |
Not applicable |
| Generic substitution risk |
Theoretical, but market demand is limited |
What is the commercial outlook for Amipaque?
Amipaque has no credible growth trajectory as an active branded pharmaceutical product. Its historical value came from an early safety advantage in myelography. That advantage was overtaken by later contrast agents and diagnostic imaging technology.
The product could retain limited historical or niche relevance in pharmacology, toxicology, or research databases. That activity would not support a material pharmaceutical revenue stream.
Key Takeaways
- Amipaque was a metrizamide-based nonionic iodinated contrast agent.
- Its principal use was intrathecal myelography.
- The product’s commercial decline resulted from newer contrast agents and MRI adoption.
- No current FDA Orange Book commercial presence or material U.S. exclusivity is identified.
- Metrizamide is a small molecule, so biosimilar risk does not apply.
- Original patents would have expired decades ago.
- No major modern Paragraph IV campaign or settlement is associated with Amipaque.
- No reliable standalone revenue history is publicly reported.
- A generic relaunch would face a shrinking clinical market rather than a patent barrier.
- Financial exposure for current drug manufacturers is effectively negligible.
FAQs About Amipaque and Metrizamide
Is Amipaque still available in the United States?
Amipaque does not have a meaningful current U.S. commercial presence and is not identified as an active marketed product in current FDA listings.
What drug replaced Amipaque?
Later low-osmolar nonionic contrast agents, including iohexol and iopamidol, replaced metrizamide in many clinical settings. MRI also reduced the need for myelography.
Is metrizamide a generic drug?
Metrizamide is the active pharmaceutical ingredient, but there is no meaningful current generic market comparable with active high-volume contrast products.
Did Amipaque generate substantial pharmaceutical revenue?
It generated commercial revenue during its historical market period, but no reliable public source reports standalone Amipaque sales. Current revenue exposure is effectively zero.
Does Amipaque have patent protection today?
No commercially meaningful patent protection is associated with the historical Amipaque product. Any original composition, formulation, or use patents would have expired long ago.
References
-
National Center for Biotechnology Information. (n.d.). PubChem compound summary for metrizamide. PubChem. https://pubchem.ncbi.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2017). Drug competition action plan. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-competition-action-plan
-
World Health Organization Collaborating Centre for Drug Statistics Methodology. (n.d.). ATC/DDD index. https://www.whocc.no/atc_ddd_index/
